Patellofemoral Pain Syndrome

Data will be featured at the ASGCT 28th Annual MeetingBRISBANE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an upcoming podium presentation of findings from its Phase 1 study of PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy candidate for osteoarthritis of the knee. The data will be presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans on May 15. The presentation will highlight how preexisting and treatment-induced neutralizing antibodies (NAbs) impact the therapy’s efficacy, safety, and redosing potential. Presentation Title: Understanding the Clinical Immunogenicity of Locally Injected HCAd Vector Provides Insight into Optimizing Dosing Strategy Presented By: MiJeong Kim, PhD, Senior Director of Translational Sciences at Pacira BioSciences Date and Time: Thursday, May 15 from 2:15–2:30 PM CT, during the “Immunogenicity/NAb Titers” oral session at ASGCT 2025 Pacira will also host a symposium on HCAd for common diseases, like osteoarthritis. Symposium Title: High-Capacity Adenoviral Vectors: Advancing Gene Therapy Beyond AAV to Deliver Cost-Effective Therapies for Common Diseases Speakers: Brendan Lee, Professor of Molecular and Human Genetics, Baylor College of MedicineDerek Jackson, Vice President, Cell & Gene Therapy Product Development at Pacira BioSciencesKilian Guse, Development of Gene Therapy for Musculoskeletal Disorders at Pacira BioSciences Date and Time: Friday, May 16 from 12:15–1:15 PM CT About PCRX-201 (enekinragene inzadenovec)PCRX-201 (enekinragene inzadenovec) features an innovative design based on the company’s proprietary high-capacity adenovirus vector platform. It is currently being studied in the fundamental, underlying chronic inflammatory processes that contribute to “wear and tear” over time in osteoarthritis of the knee, a condition that affects more than 14 million individuals in the U.S. today. In November 2024, Pacira reported promising data from a large Phase 1 study in which PCRX-201 provided sustained improvements in knee pain, stiffness, and function through two years following local administration, with a well-tolerated safety profile. PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency. PCRX-201 is the first gene therapy to achieve these clinical results and earn these regulatory designations in osteoarthritis of the knee – a testament to its promise and potential. Given the promising Phase 1 results, dosing is underway in a Phase 2 study of PCRX-201 (the ASCEND study) for the treatment of knee osteoarthritis. To learn more about PCRX-201 and the company’s clinical development program, please visit the investor events section of the company’s investor website. About PaciraPacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com. Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com

- National clinical review and contract offers an easier path to care for millions of Veterans - CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- SPR announced today that the SPRINT PNS System is now available on the Department of Veteran’s Affairs (VA) Surgical Implants-Next Generation (SING) contract via a distribution agreement with ERA Health, LLC dba Veteran’s Health Medical Supply (VHMS). The addition of SPRINT PNS to this contract will provide VA healthcare providers greater access and ease of purchase via VHMS federal contracts. The SPRINT PNS System is also currently available on the Distribution and Pricing Agreement (DAPA) and ECAT federal contracts. This new agreement with VHMS will offer physicians working in Veterans Affairs easier access to the SPRINT System and incorporate the support of VHMS staff and their longstanding relationships with purchasing staff at these facilities. The increased visibility within the VA network is a significant benefit to SPR as the SPRINT PNS System continues to see rapid adoption in the marketplace. The Veteran’s Health Administration has a significant reach throughout the U.S. with 170 VA Medical Centers and 1,193 outpatient sites of care that can deliver support to over 9.1 million Veterans enrolled in the VA health care program. “We are proud to continually expand access opportunities for those that can benefit from our SPRINT PNS treatment, and it is particularly important to provide our veterans who served our country appropriate solutions with the potential for long-term relief to help address their pain,” said Maria Bennett, President, CEO, and Founder of SPR. “Products included under this SING contract go through a comprehensive national clinical review which can help streamline the local product committee process in providing access to patients that are in need of care.” About the SPRINT PNS System The SPR® SPRINT® PNS System marks an innovative shift in the treatment of pain. Our breakthrough, 60-day treatment is a First-Line PNS™ option uniquely proposed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, knee pain, shoulder pain, post-amputation pain, and chronic and acute postoperative pain, is cleared for use up to 60 days, and is recognized by leading pain management centers. Market research indicates that this breakthrough neuromodulation treatment is a patient-preferred alternative to more invasive options. The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of postoperative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only. For additional information regarding safety and efficacy, visit: SPR Safety Information. About SPR SPR is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment of pain, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients’ lives by providing them with a minimally invasive, drug-free, surgery-free solution to manage their acute and chronic pain. SPR – Solutions for pain. Inspired by life.™ More information can be found at www.SPRPainRelief.com. SPR Contacts:Michelle McDonaldVice President – MarketingMichelle.McDonald@SPRPainRelief.com844.378.9108 Dave FolkensPublic Relations Dave.Folkens@SPRPainRelief.com612.978.6547

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- SPR announced the publication of long-term follow-up survey data from a prospective, multicenter study that demonstrated significant and sustained pain relief more than four years after treatment with 60-day minimally invasive peripheral nerve stimulation (PNS) for chronic low back pain. To understand the long-term impact of treatment with SPRINT PNS, surveys were sent to participants from a prior prospective multicenter study who reported clinically meaningful reductions in pain, disability, or pain interference. The current publication, “Four-year follow-up from a prospective, multicenter study of percutaneous 60-day peripheral nerve stimulation for chronic low back pain” appears in Pain and Therapy and the findings indicate that, “Percutaneous 60-day PNS can provide durable outcomes that are often sustained for multiple years by patients with chronic axial low back pain who subsequently avoid the need for more invasive treatment interventions.” Key Results A majority of long-term respondents (70 percent,16/23) reported clinically substantial (greater than or equal to 50 percent) pain relief and/or clinically meaningful improvements in disability (greater than or equal to 10-point improvement on the Oswestry Disability Index) four or more years after 60-day SPRINT PNS.An average of four or more years after SPRINT PNS, 70 percent (16/23) of respondents were able to avoid progression to more costly, invasive, or destructive low back pain interventions.Safety outcomes were not specifically analyzed in the long-term follow-up survey. Lead author Dr. Christopher Gilmore, MD, of Carolinas Pain Institute and SPR consultant noted, “The sustained pain relief seen in these patients is very impressive given the time since treatment and the strain that real-world physical activity can place on low back pain patients. To see four or more years of continued performance is outstanding; the fact that a majority of respondents have avoided the need for costly invasive implants or destructive surgical intervention suggests this device has had a major impact on their lives.” “We continue to be encouraged by the clinical outcomes we’re seeing in real-world settings for patients in managing their pain,” said Maria Bennett, President, CEO, and Founder of SPR. “Long-lasting pain relief of more than four years that has been experienced by some of these patients is life-changing, allowing them to reclaim their lives.” About the SPRINT PNS System The SPR® SPRINT® PNS System marks an innovative shift in the treatment of pain. Our breakthrough, 60-day treatment is a First-Line PNS™ option uniquely proposed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, knee pain, shoulder pain, post-amputation pain, and chronic and acute postoperative pain, is cleared for use up to 60 days, and is recognized by leading pain management centers. Market research indicates that this breakthrough neuromodulation treatment is a patient-preferred alternative to more invasive options. The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of postoperative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only. For additional information regarding safety and efficacy, visit: SPR Safety Information. About SPR SPR is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment of pain, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients’ lives by providing them with a minimally invasive, drug-free, surgery-free solution to manage their acute and chronic pain. SPR – Solutions for pain. Inspired by life.™ More information can be found at www.SPRPainRelief.com. SPR Contacts:Michelle McDonaldVice President – MarketingMichelle.McDonald@SPRPainRelief.com844.378.9108 Dave FolkensPublic Relations Dave.Folkens@SPRPainRelief.com612.978.6547